Table 2.
Comparison of clinical effects by androgen deprivation therapy duration
| Variable | ADT duration |
|
|---|---|---|
| Less than 1 year (n=21) | More than 1 year (n=89) | |
| Follow-up period (mo) | 8.90±2.12 | 23.83±24.18 |
| Age (yr) | 74.58±7.48 | 75.88±6.34 |
| Stage | ||
| T≤2 | 5 (23.8) | 18 (20.2) |
| T≥3 | 16 (76.2) | 71 (79.8) |
| M0 | 4 (19.0) | 15 (16.9) |
| M1 | 17 (81.0) | 74 (83.1) |
| Gleason score | 7.52±1.27 | 7.61±1.20 |
| Positive core number | 2.36±1.02 | 2.40±0.95 |
| PSA change (ng/mL) | -60.16±23.80 | -54.31±17.92 |
| Prostate volume change (%) | -51.14±8.73 | -44.12±7.33* |
| IPSS total score change | -7.27±0.72 | -5.23±0.58 |
| IPSS voiding subscore change | -4.10±0.23 | -2.65±0.50* |
| IPSS storage subscore change | -3.07±0.77 | -1.97±0.62 |
| Quality of life score change | -0.09±0.02 | -0.12±0.03 |
| Functional bladder capacity change (mL) | -6.37±1.70 | 5.86±1.10 |
| Day time voiding frequency change | -0.10±0.09 | -0.09±0.08 |
| Night time voiding frequency change | -0.09±0.11 | -0.09±0.12 |
| Qmax change (mL/sec) | 2.74±0.19 | 2.89±0.32 |
| Postvoid residual change (mL) | -26.60±8.37 | -31.33±2.95 |
Values are presented as mean±standard deviation or number (%).
ADT, androgen deprivation therapy; PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; Qmax, maximal uroflow rate.
*
P<0.05, less than 1 year vs. more than 1 year.